MR-guided whole-pelvic prostate SBRT shows favorable toxicity with optional focal boosting

In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.

KEY POINTS

  • This prospective single-institution cohort included 77 patients with high-risk localized prostate cancer, all staged with PSMA-PET/CT and treated using 1.5-T MR-guided whole-pelvic SBRT. Median follow-up was 37.7 months; 40 patients (51.9%) received a simultaneous integrated boost (SIB) to intraprostatic lesions, and 34 (44.2%) received a rectal spacer.
  • Treatment delivered 40 Gy in five fractions to the prostate, 33.5–35 Gy to proximal seminal vesicles, 25 Gy to elective pelvic lymphatics, and an optional 42.5 Gy in five fractions to MRI- or PSMA-defined intraprostatic lesions. Prostate and pelvic PTV margins were generally 5 mm, reduced to 3 mm posteriorly, with 0–2 mm around focal boost volumes; androgen deprivation was generally planned for 18–36 months.
  • Of 382 evaluable online adaptive fractions, 318 (83.2%) used adapt-to-position and 64 (16.8%) used adapt-to-shape. Complete treatment sessions required approximately 60 minutes with position adaptation and 90 minutes with shape adaptation, demonstrating the considerable resource requirements of this integrated pelvic MR-guided workflow.
  • Acute grade ≥2 GU toxicity occurred in 5/76 patients (6.6%), with no acute grade ≥2 GI toxicity. Among 72 patients evaluable for late effects, grade ≥2 GU toxicity occurred in 5 (6.9%) and GI toxicity in 7 (9.7%); one patient experienced both grade 3 hemorrhagic cystitis and grade 3 radiation proctitis, requiring hospitalization and intervention.
  • Focal boosting was not associated with significantly higher clinician-graded late GU toxicity (7.7% with SIB versus 6.1% without; p=1.000) or GI toxicity (7.7% versus 12.1%; p=0.695). However, at 24 months, boosted patients reported lower EPIC urinary summary scores (74.6 versus 86.4; p=0.017), highlighting a possible patient-reported toxicity signal not captured by grade ≥2 event rates.
  • Rectal spacer use was associated with fewer late grade ≥2 GI events: 0/30 spacer patients versus 7/42 without spacers (p=0.037). At 24 months, bowel quality-of-life scores were also higher with spacers (94.1 versus 80.3; p=0.0037), although spacer placement was clinician-selected and multiple exploratory comparisons were conducted without multiplicity adjustment.
  • Early disease-control events were uncommon: 2 biochemical recurrences (2.6%), 3 radiological recurrences (3.9%), and 1 distant metastasis (1.3%). All radiological recurrences occurred among patients without SIB or a spacer, but event numbers were insufficient for comparative efficacy assessment; patient-reported outcome data were available from only 56/77 patients (72.7%) at one or more follow-up points.

CLINICAL TAKEAWAY

Five-fraction MR-guided whole-pelvic SBRT with selective intraprostatic boosting appears feasible in carefully staged high-risk prostate cancer, with relatively low observed grade ≥2 toxicity at medium-term follow-up. Rectal spacers showed an encouraging bowel-toxicity association, while focal boosting warrants attention to patient-reported urinary effects, but neither benefit can be established causally without randomized evaluation and longer follow-up.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction